TUBITAK, Marmara Research Center, Genetic Engineering and Biotechnology Institute, P.O. Box 21, 41470 Gebze-Kocaeli, Turkey.
J Microencapsul. 2011;28(1):46-54. doi: 10.3109/02652048.2010.523795.
Biodegradable Poly(lactic-co-glycolic acid; PLGA), microspheres encapsulating the angiogenic protein recombinant human vascular endothelial growth factor (rhVEGF) were formed to achieve VEGF release in a sustained manner. These microspheres are a promising delivery system which can be used for therapeutic angiogenesis. The PLGA microspheres incorporating two different initial loading amounts of rhVEGF have been prepared by a modified water-in-oil-in-water (w/o/w) double emulsion/solvent evaporation technique. The microspheres have been characterized by particle size distribution, environmental scanning electron microscopy (ESEM), light microscopy, encapsulation efficiency and their degradation was studied in vitro. The rhVEGF released from microspheres was quantified by the competitive enzyme-linked immunosorbent assay (ELISA) and human umbilical vein endothelial cell (HUVEC) proliferation assay was used to assess biological activity of the released VEGF. The microspheres were spherical with diameters of 10-60 µm and the encapsulation efficiency was between 46% and 60%. The release kinetics of rhVEGF was studied for two different amounts: 5 µg VEGF (V5) and 50 µg VEGF (V50) per 500 mg starting polymer. The total protein (VEGF:BSA) release increased up to 4 weeks for two rhVEGF concentrations. The ELISA results showed that the burst release for V5 and V50 microspheres were 4 and 27 ng/mL, respectively. For V5, the microspheres showed an initial burst release, followed by a higher steady-state release until 14 days. VEGF release increased up to 2 weeks for V50 microsphere. HUVEC proliferation assay showed that endothelial cells responded to bioactive VEGF by proliferating and migrating.
可生物降解的聚(乳酸-共-乙醇酸;PLGA)微球包封了血管生成蛋白重组人血管内皮生长因子(rhVEGF),以实现 VEGF 的持续释放。这些微球是一种很有前途的递送系统,可用于治疗性血管生成。通过改良的水包油包水(w/o/w)双乳液/溶剂蒸发技术制备了两种不同初始加载量 rhVEGF 的 PLGA 微球。通过粒径分布、环境扫描电子显微镜(ESEM)、光学显微镜、包封效率对微球进行了表征,并在体外研究了其降解情况。通过竞争性酶联免疫吸附测定(ELISA)定量测定从微球中释放的 rhVEGF,并使用人脐静脉内皮细胞(HUVEC)增殖测定法评估释放的 VEGF 的生物活性。微球呈球形,直径为 10-60μm,包封效率在 46%-60%之间。研究了两种不同量 rhVEGF 的释放动力学:5μg VEGF(V5)和 50μg VEGF(V50)/500mg 起始聚合物。两种 rhVEGF 浓度的总蛋白(VEGF:BSA)释放持续增加至 4 周。ELISA 结果表明,V5 和 V50 微球的突释分别为 4 和 27ng/mL。对于 V5,微球表现出初始突释,然后是更高的稳态释放,持续到 14 天。对于 V50 微球,VEGF 释放增加至 2 周。HUVEC 增殖测定表明内皮细胞通过增殖和迁移对生物活性 VEGF 作出反应。